TCGA-QK-A6IG-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.050684932
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.610
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.470
- DNA_REPAIR+0.440
- INTERFERON_ALPHA_RESPONSE+0.430
- OXIDATIVE_PHOSPHORYLATION+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- INTERFERON_GAMMA_RESPONSE+0.290
- ANGIOGENESIS+0.250
Top 10 suppressed
- KRAS_SIGNALING_DN-0.290
- PROTEIN_SECRETION-0.290
- ESTROGEN_RESPONSE_EARLY-0.280
- TGF_BETA_SIGNALING-0.270
- UV_RESPONSE_DN-0.240
- HEME_METABOLISM-0.210
- HEDGEHOG_SIGNALING-0.200
- ANDROGEN_RESPONSE-0.190
- ESTROGEN_RESPONSE_LATE-0.190
- NOTCH_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-5966-01A-11R-1686-07 | — | — | 0.889 |
| 2 | 784b2763-b9be-4b7f-84b0-f5ec6f784717 | — | — | 0.841 |
| 3 | DRR168607 | — | — | 0.837 |
| 4 | SRR8518360 | — | E | 0.835 |
| 5 | FD76D38B-2A54-4F1A-B7C0-EF268F9D9A0E | — | — | 0.826 |
| 6 | d9780581-dfca-4e83-9bb4-4836f22d910e | — | — | 0.823 |
| 7 | BS_HE57E1RP | Med | Medulloblastoma | 0.822 |
| 8 | B1A2365C-5491-4E85-AE7E-97B9DB8FF8D1 | — | — | 0.819 |
| 9 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.815 |
| 10 | BSR_09_0163_C1_S96 | — | C | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.610 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |